JP2024102205A5 - - Google Patents

Download PDF

Info

Publication number
JP2024102205A5
JP2024102205A5 JP2024074264A JP2024074264A JP2024102205A5 JP 2024102205 A5 JP2024102205 A5 JP 2024102205A5 JP 2024074264 A JP2024074264 A JP 2024074264A JP 2024074264 A JP2024074264 A JP 2024074264A JP 2024102205 A5 JP2024102205 A5 JP 2024102205A5
Authority
JP
Japan
Prior art keywords
dose
ifnar1
inhibitor
injection device
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024074264A
Other languages
English (en)
Japanese (ja)
Other versions
JP7805393B2 (ja
JP2024102205A (ja
Filing date
Publication date
Priority claimed from JP2023562678A external-priority patent/JP7484027B2/ja
Application filed filed Critical
Publication of JP2024102205A publication Critical patent/JP2024102205A/ja
Publication of JP2024102205A5 publication Critical patent/JP2024102205A5/ja
Priority to JP2026003230A priority Critical patent/JP2026086416A/ja
Application granted granted Critical
Publication of JP7805393B2 publication Critical patent/JP7805393B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024074264A 2021-04-23 2024-05-01 皮下注射のための抗ｉｆｎａｒ１投薬計画 Active JP7805393B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026003230A JP2026086416A (ja) 2021-04-23 2026-01-13 皮下注射のための抗ｉｆｎａｒ１投薬計画

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163178739P 2021-04-23 2021-04-23
US63/178,739 2021-04-23
US202163245285P 2021-09-17 2021-09-17
US63/245,285 2021-09-17
US202163272851P 2021-10-28 2021-10-28
US63/272,851 2021-10-28
JP2023562678A JP7484027B2 (ja) 2021-04-23 2022-04-21 皮下注射のための抗ｉｆｎａｒ１投薬計画
PCT/EP2022/060592 WO2022223714A1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023562678A Division JP7484027B2 (ja) 2021-04-23 2022-04-21 皮下注射のための抗ｉｆｎａｒ１投薬計画

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026003230A Division JP2026086416A (ja) 2021-04-23 2026-01-13 皮下注射のための抗ｉｆｎａｒ１投薬計画

Publications (3)

Publication Number Publication Date
JP2024102205A JP2024102205A (ja) 2024-07-30
JP2024102205A5 true JP2024102205A5 (enExample) 2024-10-31
JP7805393B2 JP7805393B2 (ja) 2026-01-23

Family

ID=81750490

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023562678A Active JP7484027B2 (ja) 2021-04-23 2022-04-21 皮下注射のための抗ｉｆｎａｒ１投薬計画
JP2024074264A Active JP7805393B2 (ja) 2021-04-23 2024-05-01 皮下注射のための抗ｉｆｎａｒ１投薬計画
JP2026003230A Pending JP2026086416A (ja) 2021-04-23 2026-01-13 皮下注射のための抗ｉｆｎａｒ１投薬計画

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023562678A Active JP7484027B2 (ja) 2021-04-23 2022-04-21 皮下注射のための抗ｉｆｎａｒ１投薬計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026003230A Pending JP2026086416A (ja) 2021-04-23 2026-01-13 皮下注射のための抗ｉｆｎａｒ１投薬計画

Country Status (25)

Country Link
US (4) US20220340669A1 (enExample)
EP (2) EP4114465B1 (enExample)
JP (3) JP7484027B2 (enExample)
KR (2) KR20230166134A (enExample)
CN (2) CN120514844A (enExample)
AU (2) AU2022260531B2 (enExample)
BR (1) BR112023021761A2 (enExample)
CA (1) CA3216387A1 (enExample)
CL (1) CL2023003114A1 (enExample)
CO (1) CO2023015498A2 (enExample)
DK (1) DK4114465T5 (enExample)
ES (1) ES2963757T3 (enExample)
FI (1) FI4114465T3 (enExample)
HR (1) HRP20231255T1 (enExample)
HU (1) HUE063562T2 (enExample)
IL (2) IL327109A (enExample)
LT (1) LT4114465T (enExample)
MX (1) MX2023012465A (enExample)
PL (1) PL4114465T3 (enExample)
PT (1) PT4114465T (enExample)
RS (1) RS64821B1 (enExample)
SI (1) SI4114465T1 (enExample)
SM (1) SMT202300382T1 (enExample)
TW (1) TW202317182A (enExample)
WO (1) WO2022223714A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643237T3 (es) * 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
KR20230110304A (ko) * 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
AU2022260544A1 (en) * 2021-04-23 2023-11-30 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
TW202317617A (zh) * 2021-04-23 2023-05-01 瑞典商阿斯特捷利康公司 皮膚紅斑狼瘡之治療
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
EP4713361A1 (en) 2023-05-19 2026-03-25 AstraZeneca AB Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044406A1 (en) 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
ES2643237T3 (es) * 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2651866C (en) 2006-05-11 2014-10-28 Universiteit Gent Sialoadhesin-related compositions and methods
WO2008070135A2 (en) 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus
CA2692784C (en) 2007-07-12 2018-10-02 The Brigham And Women's Hospital, Inc. Compositions and methods for diagnosing and assessing inflammatory myopathies
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
US20110287022A1 (en) 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
CN104603152A (zh) * 2012-06-13 2015-05-06 米迪缪尼有限公司 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
SG11202101946YA (en) * 2018-09-18 2021-04-29 I Mab Biopharma Hangzhou Co Ltd Anti-ifnar1 antibodies for treating autoimmune diseases
EP3924383A1 (en) * 2019-02-15 2021-12-22 Astrazeneca AB Type i interferon-mediated disorders
DK4058060T3 (da) 2019-11-11 2025-03-17 Astrazeneca Ab Type i-interferon-hæmning ved systemisk lupus erythematosus
JP2023527054A (ja) 2020-05-29 2023-06-26 アストラゼネカ・アクチエボラーグ Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
KR20230110304A (ko) * 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
AU2022260544A1 (en) 2021-04-23 2023-11-30 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Similar Documents

Publication Publication Date Title
US6623736B2 (en) Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
ES2963757T3 (es) Régimen de dosificación de anti-ifnar1 para inyección subcutánea
JP2025172841A5 (enExample)
US6471961B1 (en) Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
JP7164530B2 (ja) Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2022160685A5 (enExample)
JP2023548858A5 (enExample)
JP2015533806A (ja) 関節リウマチの治療
JP2024510142A5 (enExample)
EP4612183A1 (en) Methods for treating hand and foot dermatitis by administering an il-4r antagonist
JP2024537288A5 (enExample)
EP4707302A2 (en) Ofatumumab for treating ms while maintaining serum igg
EP0303687B1 (en) Compositions for enhancing adcc therapy
Pitarokoili et al. Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis
JP2024517087A5 (enExample)
WO2017221174A1 (en) Methods of treating vitiligo using interleukin-17 (il-17) antibodies
AU2019364239B2 (en) Pan-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
CN115515978A (zh) 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体
KR20220104789A (ko) 류마티스 관절염의 치료를 위한 btk 억제제 및 아바타셉트의 조합물
WO2021018191A1 (zh) Il-17拮抗剂治疗自身免疫疾病的方法
WO2021111377A2 (en) Methods of treating lichen planus using interleukin-17 (il-17) antagonists
US11993656B2 (en) Method of treating IgG4-related disease
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r